# NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

> **NCT03399448** · PHASE1 · TERMINATED · sponsor: **University of Pennsylvania** · enrollment: 3 (actual)

## Conditions studied

- Multiple Myeloma
- Melanoma
- Synovial Sarcoma
- Myxoid/Round Cell Liposarcoma

## Interventions

- **BIOLOGICAL:** NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DEVICE:** NY-ESO-1 expression testing

## Key facts

- **NCT ID:** NCT03399448
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-05
- **Primary completion:** 2020-02-29
- **Final completion:** 2020-10-09
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Sponsor has terminated trial to pursue other targets.
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03399448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03399448, "NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03399448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*